Table 3.
EVLP features and its efficacy of improving donor lungs.
| Author | Reason for EVLP | Technological type | EVLP solution | EVLP duration (min) | PaO2/FiO2 100% (mmHg) | Accepted/total (pair) | Conversion rate | |
|---|---|---|---|---|---|---|---|---|
| Pre EVLP | Post EVLP | |||||||
| Koch et al. [20] | Marginal donor | Toronto | Steen solution with meropenem, dexamethasone and heparin | 240 | 273±70 | 401±35 | 9/11 | 81.8% |
| Warnecke et al. [16] | Random assignment (standard donor) | OCS | OCS/LPD solution with ABO-compatible erythrocyte | 300 | 438.5± 80.0 | 455.5± 111.1 | 150/151 | 99.3% |
| Nilsson et al. [21] | Marginal donor | Lund | Steen solution mixed with red blood cells, heparin and meropenem | 200±94 | 229.52±90 | 438.79±75 | 49.5/61 | 81.0% |
| Zhang et al. [22] | Marginal donor | Toronto | Steen solution with cefuroxime, dexamethasone and heparin | 240 (IQR 84–100.8) | 285.77± 99.76 | NA | 9/10 | 90.0% |
| Slama et al. [17] | Random assignment (standard donor) | Toronto | Steen solution with heparin, cefuroxime and methylprednisolone | 266 (245–329) | 514 (290–626) | NA | 37/39 | 94.9% |
| Luc et al. [18] | Marginal donor | OCS | OCS solution | 210±101 | 367±119 | 500±83 | 7/7 | 100% |
| Wallinder et al. 2016 [23] | Marginal donor | Lund | Steen Solution with red blood cells | 208 (100–577) | 217.52± 85.1 | 477.04 (288.77–594.05) | 24.5/32 | 76.6% |
| Fisher et al. [24] | Marginal donor | Hybrid EVLP (combining Toronto and Lund); Lund | Hybrid: Steen solution; Lund: Steen solution with red cells | NA | 299 (95–535) | 381.5 (74–638) | 18/53 | 34% |
| Machuca et al. [19] | Marginal donor | Toronto | Steen solution with heparin, methylprednisolone and imipenem/cilastatin | 240–360 | 380±103 | NA | 28/35 | 80% |
| Tikkanen et al. [25] | Marginal donor | Toronto | Steen solution | 175 (73–383) | 332.5± 127.0 | 346.1± 104.0 | 63/73 | 86% |
| Fildes et al. [26] | Marginal donor | Lund | Steen solution with blood cells, trometamol and antibiotic | 240 | <300 | >300 | 9/9 | 100% |
| Sanchez et al. [15] | Marginal donor | Toronto | Steen solution | 180–360 | NA | NA | 42/76 | 55% |
| Sage et al. [29] | Marginal donor | Toronto | Steen solution | 243 (124–460) | 274 (162–404) | 511 (378–668) | 31/32 | 96.6% |
| Boffini et al. [28] | Marginal donor | Toronto | Steen solution with antibiotics, heparin and methylprednisolone | 282.8± 57.1 | 200±85 | 438±8 | 8/11 | 73.0% |
| Valenza et al. [4] | Marginal donor | Lund | Steen solution with red blood cells, methylprednisolone, cefazolin, and heparin | 268±104 | 264±78 | 518±55 | 7/8 | 87.5% |
| Wallinder et al. 2014 [29] | Marginal donor | Lund | Steen Solution with red blood cells | 191 (156–577) | 209.27 (68.26–313.53) | 447.04 (303.02–572.3) | 10/11 | 90.9% |
| Cypel et al. [30] | Marginal donor | Toronto | Steen solution with methylprednisolone, imipenem/cilastatin, and heparin | 240–360 | 334 (143–532) | Median 513 | 50/58 | 86.2% |
| Zych et al. [31] | Marginal donor | Toronto | Steen Solution with heparin, methylprednisolone, and antibiotics | 141±28.83 | 317.73±105.98 | 429.94± 68.26 | 6/13 | 46.2% |
| Aigner et al. [32] | Marginal donor | Toronto | Steen solution | 199 (171–290) | 216 (133–271) | 466 (434–525) | 9/13 | 69.2% |
| Lindstedt et al. [33] | Marginal donor | Lund | Steen solution with ABO-compatible erythrocyte, imipenem, insulin, and heparin | 89 (66–121) | 158.26 (86.26–215.27) | 515.29 (387.03–596.3) | 6/8 | 75.0% |
Data are presented as n/N, mean±SD, median (range) or median (IQR). NA – not available; SD – standard deviation; IQR – inter-quartile range.